{"id":54170,"date":"2022-11-11T13:21:37","date_gmt":"2022-11-11T12:21:37","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=54170"},"modified":"2022-11-14T16:10:13","modified_gmt":"2022-11-14T15:10:13","slug":"open-targets-consortium-welcomes-genentech-as-newest-member","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/","title":{"rendered":"Open Targets consortium welcomes Genentech as newest member"},"content":{"rendered":"\n<p>Genentech, a member of the Roche group, has joined the <a href=\"https:\/\/www.opentargets.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">Open Targets<\/a> consortium. <a href=\"https:\/\/www.gene.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Genentech<\/a> is the second company to join the industry-academic partnership this year and will collaborate with other consortium members including EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Bristol Myers Squibb, Sanofi, and Pfizer.<\/p>\n\n\n\n<p>Clinical trials are much more likely to succeed if the therapies tested are backed by genetic evidence. Open Targets was founded in 2014 with the aim of using the information generated by genetic sequencing and genomics studies to systematically improve the selection of targets for drug development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Target identification and prioritisation<\/strong><\/h2>\n\n\n\n<p>Open Targets partners collaborate on innovative experimental and informatics projects, working pre-competitively to bridge the gap between pharmaceutical companies and not-for-profit research institutes. Using systematic, large-scale experimental and informatics approaches, Open Targets projects identify causal links between targets, biological pathways, and disease.&nbsp;<\/p>\n\n\n\n<p>\u201cGenentech is an excellent fit for Open Targets,\u201d said <a href=\"https:\/\/www.ebi.ac.uk\/people\/person\/ian-dunham\/\">Ian Dunham, Director of Open Targets<\/a>. \u201cTheir thinking on the value of large scale genetics and genomics approaches in target identification and prioritisation is very compatible with the consortium, and we are already looking forward to working together on existing projects and developing more exciting new projects in our focus areas.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Working in partnership&nbsp;<\/strong><\/h2>\n\n\n\n<p>Open Targets addresses all aspects of human health and disease, with a particular focus on immunology and inflammation, oncology, and neurodegeneration research. The partnership is committed to rapid publication to openly share experimental data, informatics methods, and other knowledge generated by the consortium with the broader scientific community.<\/p>\n\n\n\n<p>\u201cOpen Targets brings a team of multidisciplinary scientists together to work in partnership on projects that no one partner could do alone,\u201d said <a href=\"https:\/\/www.sanger.ac.uk\/person\/trynka-gosia\/\">Gosia Trynka, Experimental Science Director of Open Targets and Group Leader at the Wellcome Sanger Institute<\/a>. \u201cWelcoming Genentech into our community, sharing our research with them, and learning from their approaches will strengthen our exploration of new targets and biology that can lead to novel, safe and effective medicines.\u201d<\/p>\n\n\n\n<p>This press release was originally published on the <a href=\"https:\/\/www.opentargets.org\/news\/genentech-joins-Open-Targets-Nov-2022.html\">Open Targets website<\/a>. <\/p>\n\n\n\n<article class=\"vf-card vf-card--brand vf-card--striped vf-u-margin__bottom--800\" default>\n  <div class=\"vf-card__content | vf-stack vf-stack--400\">\n      <h3 class=\"vf-card__heading\">\n              <a class=\"vf-card__link\" href=\"https:\/\/www.opentargets.org\/\">\n      More about Open Targets       <svg aria-hidden=\"true\" class=\"vf-card__heading__icon | vf-icon vf-icon-arrow--inline-end\" width=\"1em\" height=\"1em\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n          <path d=\"M0 12c0 6.627 5.373 12 12 12s12-5.373 12-12S18.627 0 12 0C5.376.008.008 5.376 0 12zm13.707-5.209l4.5 4.5a1 1 0 010 1.414l-4.5 4.5a1 1 0 01-1.414-1.414l2.366-2.367a.25.25 0 00-.177-.424H6a1 1 0 010-2h8.482a.25.25 0 00.177-.427l-2.366-2.368a1 1 0 011.414-1.414z\" fill=\"currentColor\" fill-rule=\"nonzero\"><\/path>\n       <\/svg>\n        <\/a>\n          <\/h3>\n                <p class=\"vf-card__text\">Open Targets is a pre-competitive, public-private partnership that uses human genetics and genomics data to systematically identify and prioritise drug targets. Through large-scale genomic experiments and the development of innovative computational techniques, the partnership aims to help researchers select the best targets for the development of new therapies.\r\n<br \/>\r\nFounded in 2014, Open Targets brings together the world-class expertise of EMBL\u2019s European Bioinformatics Institute and the Wellcome Sanger Institute with the drug discovery capabilities of leading industry partners, currently GSK, BMS, Sanofi, Pfizer, and Genentech. The consortium also collaborates globally to engage with expertise and capabilities aligned with its mission.<\/p>\n      <\/div>\n<\/article>\n\n","protected":false},"excerpt":{"rendered":"<p>Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium.<\/p>\n","protected":false},"author":122,"featured_media":54172,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[11052,2],"tags":[28,36,42,763,1748],"embl_taxonomy":[11100],"class_list":["post-54170","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-announcements","category-science","tag-bioinformatics","tag-embl-ebi","tag-genomics","tag-open-targets","tag-press-release","embl_taxonomy-open-targets"],"acf":{"featured":true,"show_featured_image":false,"field_target_display":"both","field_article_language":{"value":"english","label":"English"},"article_intro":"<p>Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium<\/p>\n","related_links":[{"link_description":"Open Targets","link_url":"https:\/\/www.opentargets.org\/"},{"link_description":"Genentech ","link_url":"https:\/\/www.gene.com\/"}],"source_article":false,"in_this_article":false,"press_contact":"None","article_translations":false,"languages":"","vf_locked":false},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"18699e63-ed43-40c6-8d1c-203db7ed72ee\";i:2;s:36:\"418846e9-61d5-456f-a171-9ec5018d2a02\";}","parents":[],"name":["Open Targets"],"slug":"open-targets","description":"What &gt; EMBL-EBI Services &gt; Open Targets"}],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Open Targets consortium welcomes Genentech as newest member | EMBL<\/title>\n<meta name=\"description\" content=\"Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Open Targets consortium welcomes Genentech as newest member | EMBL\" \/>\n<meta property=\"og:description\" content=\"Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-11T12:21:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-14T15:10:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Helena Cornu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Helena Cornu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/\"},\"author\":{\"name\":\"Helena Cornu\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/28025546c614d54b4274ff601f5e37b0\"},\"headline\":\"Open Targets consortium welcomes Genentech as newest member\",\"datePublished\":\"2022-11-11T12:21:37+00:00\",\"dateModified\":\"2022-11-14T15:10:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/\"},\"wordCount\":346,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\",\"keywords\":[\"bioinformatics\",\"embl-ebi\",\"genomics\",\"open targets\",\"press release\"],\"articleSection\":[\"Announcements\",\"Science\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/\",\"url\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/\",\"name\":\"Open Targets consortium welcomes Genentech as newest member | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\",\"datePublished\":\"2022-11-11T12:21:37+00:00\",\"dateModified\":\"2022-11-14T15:10:13+00:00\",\"description\":\"Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg\",\"width\":1000,\"height\":600,\"caption\":\"Open Targets. Credit: Karen Arnott\/EMBL-EBI\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/28025546c614d54b4274ff601f5e37b0\",\"name\":\"Helena Cornu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/eff3a8ffe7da00a022e3fead24b6197e417a8b3db2e3db577e75e5fd39ac9701?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/eff3a8ffe7da00a022e3fead24b6197e417a8b3db2e3db577e75e5fd39ac9701?s=96&d=mm&r=g\",\"caption\":\"Helena Cornu\"},\"url\":\"https:\/\/www.embl.org\/news\/author\/hcornu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Open Targets consortium welcomes Genentech as newest member | EMBL","description":"Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/","og_locale":"en_US","og_type":"article","og_title":"Open Targets consortium welcomes Genentech as newest member | EMBL","og_description":"Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium","og_url":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2022-11-11T12:21:37+00:00","article_modified_time":"2022-11-14T15:10:13+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","type":"image\/jpeg"}],"author":"Helena Cornu","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Helena Cornu","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/"},"author":{"name":"Helena Cornu","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/28025546c614d54b4274ff601f5e37b0"},"headline":"Open Targets consortium welcomes Genentech as newest member","datePublished":"2022-11-11T12:21:37+00:00","dateModified":"2022-11-14T15:10:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/"},"wordCount":346,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","keywords":["bioinformatics","embl-ebi","genomics","open targets","press release"],"articleSection":["Announcements","Science"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/","url":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/","name":"Open Targets consortium welcomes Genentech as newest member | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","datePublished":"2022-11-11T12:21:37+00:00","dateModified":"2022-11-14T15:10:13+00:00","description":"Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/science\/open-targets-consortium-welcomes-genentech-as-newest-member\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","width":1000,"height":600,"caption":"Open Targets. Credit: Karen Arnott\/EMBL-EBI"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/28025546c614d54b4274ff601f5e37b0","name":"Helena Cornu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/eff3a8ffe7da00a022e3fead24b6197e417a8b3db2e3db577e75e5fd39ac9701?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eff3a8ffe7da00a022e3fead24b6197e417a8b3db2e3db577e75e5fd39ac9701?s=96&d=mm&r=g","caption":"Helena Cornu"},"url":"https:\/\/www.embl.org\/news\/author\/hcornu\/"}]}},"field_target_display":"both","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/2022-OpenTargets-partner-with-Genentech-1-e1668169270580.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/54170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/122"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=54170"}],"version-history":[{"count":12,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/54170\/revisions"}],"predecessor-version":[{"id":54222,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/54170\/revisions\/54222"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/54172"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=54170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=54170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=54170"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=54170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}